Benjamin Wolozin receives $500,000 award in Alzheimer's Disease Drug Discovery Research

Download PDF Copy

Reviewed

Boston University Medical CenterDec 22 2015

Research that leads to improved therapies for Alzheimer's disease (AD) patients is one goal of Boston University School of Medicine professor of pharmacology and neurology Benjamin Wolozin, MD, PhD. He was one of six researchers awarded a two-year, $500,000 award in Alzheimer's Disease Drug Discovery Research by the Edward N. & Della L. Thome Memorial Foundation.

Wolozin has been studying the pathophysiology of AD, amyotrophic lateral sclerosis and Parkinson's disease (PD) for nearly 20 years and has made numerous contributions to the current field of understanding of neurodegenerative diseases. He has published more than 150 papers and book chapters on the topic in such high impact journals as Science, Nature and PNAS. He also holds four patents in the AD and PD fields and is the co-founder of the biotechnology company Aquinnah Pharmaceuticals, Inc.

The Edward N. & Della L. Thome Memorial Foundation was created in 2002 with the mission of advancing the health of older adults through support of direct service projects and medical research on disease and disorders affecting them. Each year they award $500,000 to a faculty member at a non-profit academic, medical, non-governmental or research institution in the United States with the purpose of furthering this objective.

The Edward N. & Della L. Thome Memorial Foundation, Bank of America, N.A., Trustee, Awards Program in Alzheimer's Disease Drug Discovery Research is administered by The Medical Foundation, a division of Health Resources in Action (HRiA). HRiA is a nonprofit organization in Boston that advances public health and medical research.

Source:

Boston University Medical Center

Posted in: Medical Research News | Medical Condition News

Tags: Alzheimer's Disease, Amyloidosis, Amyotrophic Lateral Sclerosis, Arthritis, Biotechnology, Cancer, Cardiovascular Disease, Dermatology, Drug Discovery, Healthcare, Hospital, Infectious Diseases, Medical Research, Medicine, Neurodegenerative Diseases, Neurology, Parkinson's Disease, Pathophysiology, Pharmaceuticals, Pharmacology, Public Health, Research, Sclerosis

Comments (1)

Download PDF Copy

Comments

Greeley Miklashek, MD (retired) on Benjamin Wolozin receives $500,000 award in Alzheimer's Disease Drug Discovery Research

Greeley Miklashek, MD (retired) says:

December 23, 2015 at 2:43 PM

I am a retired neuropsychiatrist, retired after a 40 year career as a clinician and teacher. I treated 25,000 patients and wrote 1,000,000 psychotropic Rx. I am very suspicious of the medical industry being built around the misdiagnosis of AD. In fact, Dr. Alzheimer described a triad of post-mortem histopathological findings in sections from the brains of deceased patients who suffered from dementias prior to their deaths. Technically, this was never a "disease" per se. In my practice, I treated hundreds of patients suffering from early short-term memory loss and their memory function was totally restored. What I and my patients discovered was a set of transcription factor deficiencies including one or more of the following: Vit. B12, thyroid hormones, estrogen or testosterone, and cortisol (either too much or too little). Most often, they could solve their memory problems with a visit to the nearest health food store for some B vits, Kelp, DHEA, or pregnenalone. Sadly, this simple, cheap, safe, and effective treatment strategy has never been published, as far as I know. Educate yourself with the net, which is what I always recommended to my patients.

0 0

Reply